These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32661549)

  • 1. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.
    Santangelo A; Rossato M; Lombardi G; Benfatto S; Lavezzari D; De Salvo GL; Indraccolo S; Dechecchi MC; Prandini P; Gambari R; Scapoli C; Di Gennaro G; Caccese M; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Lippi G; Delledonne M; Zagonel V; Cabrini G
    Neuro Oncol; 2021 Feb; 23(2):264-276. PubMed ID: 32661549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing.
    Agrawal R; Pandey P; Jha P; Dwivedi V; Sarkar C; Kulshreshtha R
    BMC Genomics; 2014 Aug; 15(1):686. PubMed ID: 25129238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
    Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
    Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G
    Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles.
    Zottel A; Šamec N; Kump A; Raspor Dall'Olio LR; Pužar Dominkuš P; Romih R; Hudoklin S; Mlakar J; Nikitin D; Sorokin M; Buzdin A; Jovčevska I; Komel R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
    Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib in glioblastoma recurrence: A case report.
    Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
    Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
    Rudà R; Bruno F; Pellerino A; Pronello E; Palmiero R; Bertero L; Crasto S; Polo V; Vitaliani R; Trincia E; Internò V; Porta C; Soffietti R
    J Neurooncol; 2022 Nov; 160(2):389-402. PubMed ID: 36309895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
    Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
    Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
    Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
    Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
    Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
    PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor candidate 3.
    Liang Q; Wang K; Wang B; Cai Q
    Sci Rep; 2017 Mar; 7():44705. PubMed ID: 28303930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
    Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
    Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature.
    Tzaridis T; Reiners KS; Weller J; Bachurski D; Schäfer N; Schaub C; Hallek M; Scheffler B; Glas M; Herrlinger U; Wild S; Coch C; Hartmann G
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between magnetic resonance imaging features and miRNA gene expression in patients with glioblastoma multiforme.
    Li WB; Chen HY; Zhang W; Yan W; Shi R; Li SW; Jiang T
    Chin Med J (Engl); 2013; 126(15):2881-5. PubMed ID: 23924460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA profiling in patients with glioblastoma: a survival analysis.
    Zhao H; Shen J; Hodges TR; Song R; Fuller GN; Heimberger AB
    Mol Cancer; 2017 Mar; 16(1):59. PubMed ID: 28284220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
    Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
    Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.
    Besse A; Sana J; Lakomy R; Kren L; Fadrus P; Smrcka M; Hermanova M; Jancalek R; Reguli S; Lipina R; Svoboda M; Slampa P; Slaby O
    Tumour Biol; 2016 Jun; 37(6):7719-27. PubMed ID: 26692101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
    Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
    Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.